Evaluation of Serum Biomarkers Associated with Radiographic Progression in Methotrexate-naive Rheumatoid Arthritis Patients Treated with Methotrexate or Golimumab

REFERENCES

1. 1.↵
   1. Welsing PM,
   2. Landewe RB,
   3. van Riel PL,
   4. Boers M,
   5. van Gestel AM,
   6. van der Linden S,
   7. et al.

   The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum 2004;50:2082–93.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. van der Heijde DM

   . Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 1995;34 Suppl 2:74–8.

   OpenUrlPubMed
3. 3.↵
   1. Bresnihan B

   . Rheumatoid arthritis: Principles of early treatment. J Rheumatol Suppl. 2002 Nov;66:9–12.
4. 4.↵
   1. Keystone E

   . Recent concepts in the inhibition of radiographic progression with biologics. Curr Opin Rheumatol 2009;21:231–7.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Smolen JS,
   2. van der Heijde DM,
   3. St. Clair EW,
   4. Emery P,
   5. Bathon JM,
   6. Keystone E,
   7. et al.

   Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006;54:702–10.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Weinblatt ME,
   2. Keystone EC,
   3. Cohen MD,
   4. Freundlich B,
   5. Li J,
   6. Chon Y,
   7. et al.

   Factors associated with radiographic progression in patients with rheumatoid arthritis who were treated with methotrexate. J Rheumatol 2011;38:242–6.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Young-Min S,
   2. Cawston T,
   3. Marshall N,
   4. Coady D,
   5. Christgau S,
   6. Saxne T,
   7. et al.

   Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum 2007;56:3236–47.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Meyer O,
   2. Labarre C,
   3. Dougados M,
   4. Goupille P,
   5. Cantagrel A,
   6. Dubois A,
   7. et al.

   Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003;62:120–6.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Nishimura K,
   2. Sugiyama D,
   3. Kogata Y,
   4. Tsuji G,
   5. Nakazawa T,
   6. Kawano S,
   7. et al.

   Meta-analysis: Diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007;146:797–808.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Aletaha D,
    2. Alasti F,
    3. Smolen JS

    . Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity. Ann Rheum Dis 2012 Jul 13 [E-pub ahead of print].
11. 11.↵
    Simponi: Package insert. Horsham, PA: Janssen Biotech Inc.; 2011.
12. 12.↵
    1. Keystone EC,
    2. Genovese MC,
    3. Klareskog L,
    4. Hsia EC,
    5. Hall ST,
    6. Miranda PC,
    7. et al.

    Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: The GO-FORWARD Study. Ann Rheum Dis 2009;68:789–96.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Visvanathan S,
    2. Rahman MU,
    3. Keystone E,
    4. Genovese M,
    5. Klareskog L,
    6. Hsia E,
    7. et al.

    Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study. Arthritis Res Ther 2010;12:R211.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Emery P,
    2. Fleischmann RM,
    3. Moreland LW,
    4. Hsia EC,
    5. Strusberg I,
    6. Durez P,
    7. et al.

    Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009;60:2272–83.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Emery P,
    2. Fleischmann R,
    3. van der Heijde D,
    4. Keystone EC,
    5. Genovese MC,
    6. Conaghan PG,
    7. et al.

    The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum 2011;63:1200–10.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. van der Heijde D

    . How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000;27:261–3.

    OpenUrlPubMed
17. 17.↵
    1. Breedveld FC,
    2. Weisman MH,
    3. Kavanaugh AF,
    4. Cohen SB,
    5. Pavelka K,
    6. van Vollenhoven R,
    7. et al.

    The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26–37.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Genovese MC,
    2. Bathon JM,
    3. Martin RW,
    4. Fleischmann RM,
    5. Tesser JR,
    6. Schiff MH,
    7. et al.

    Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443–50.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Gladman DD,
    2. Mease PJ,
    3. Ritchlin CT,
    4. Choy EH,
    5. Sharp JT,
    6. Ory PA,
    7. et al.

    Adalimumab for long-term treatment of psoriatic arthritis: Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007;56:476–88.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Lee HY,
    2. Jeon HS,
    3. Song EK,
    4. Han MK,
    5. Park SI,
    6. Lee SI,
    7. et al.

    CD40 ligation of rheumatoid synovial fibroblasts regulates RANKL-mediated osteoclastogenesis: evidence of NF-kappa B-dependent, CD40-mediated bone destruction in rheumatoid arthritis. Arthritis Rheum 2006;54:1747–58.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Guise TA

    . Breaking down bone: New insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases. Genes Dev 2009;23:2117–23.

    OpenUrlAbstract/FREE Full Text
22. 22.↵
    1. Schneider MR,
    2. Sibilia M,
    3. Erben RG

    . The EGFR network in bone biology and pathology. Trends Endocrinol Metab 2009;20:517–24.

    OpenUrlCrossRefPubMed